Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5935
    +0.0001 (+0.02%)
     
  • NZD/EUR

    0.5545
    +0.0004 (+0.07%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.83
    +0.02 (+0.02%)
     
  • GOLD

    2,329.00
    -9.40 (-0.40%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • NZD/JPY

    92.0850
    +0.3190 (+0.35%)
     

How Analysts View Merck Stock, Pre-Q3 Results

How Analysts View Merck Stock, Pre-Q3 Results

Between October 11 and 12, Merck (MRK) stock rose ~2.11% from $68.37 to close at $69.81. It was 32% higher than its 52-week low of $52.83 on April 3. Merck’s 52-week high is $72.89, reached on October 10.